ReviewFrontiers in cardiovascular medicine2020
Gender-Related Differences in Heart Failure Biomarkers.
Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Trial
- Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes.Current cardiology reports · 2026Review
- Circulating CD38 shows stronger association with incident heart failure in women despite lower levels: sex differences and kidney-function context.Biology of sex differences · 2026Article
- Circadian troponin dynamics reveal sex-specific signals for acute coronary syndrome evaluation.Internal and emergency medicine · 2026Article
- Heart Failure and Atrial Fibrillation in Women: Pathophysiological Links, Clinical Challenges, and Therapeutic Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Sex-stratified early biomarker model identifies lactate as the key predictor of in-hospital deterioration in acute heart failure.Frontiers in cardiovascular medicine · 2026Article
- NT-proBNP and its association with autonomous aldosterone production in primary aldosteronism.Therapeutic advances in endocrinology and metabolism · 2026Article
- Cardiovascular risk prediction in women: rethinking traditional approaches through precision medicine.Frontiers in global women's health · 2026Review
- The expression pattern and prognostic relevance of p120-catenin, COL4A2 and SOX10 in glioma.Frontiers in oncology · 2026Article
- Unravelling Sex Disparities in the Pathophysiology of Atrial Fibrillation: Review of the Current Evidence.Journal of cardiovascular electrophysiology · 2025Review
- A Comprehensive Profile of Heart Failure Patients Across Ejection Fraction Subtypes: Insights from a Single-Center Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Impact of gender on clinical characteristics in patients with atrial fibrillation and STEMI.Journal of medicine and life · 2025Article
- The Association Between Chronic Heart Failure and Metabolic Syndrome Increases the Cost of Hospitalization.Healthcare (Basel, Switzerland) · 2025Article
- The Impact of Metformin on BNP Levels: A Potential Cardioprotective Role in Type 2 Diabetes.Journal of clinical medicine · 2025Article
- Diagnosing Heart Failure with Preserved Ejection Fraction in Obese Patients.Journal of clinical medicine · 2025Review
- Effects of Age, Sex, and Exercise on Measurement of Serum CTnI Levels and Some Parameters Related to the Cardiovascular Capacity of Caspian Horses.Veterinary medicine and science · 2025Article
- Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential.Frontiers in genetics · 2025Review
- Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF.Frontiers in cardiovascular medicine · 2025Article
- Sex Differences in Heart Failure: A Step Forward.Interventional cardiology (London, England) · 2025Review
- Improvement initiatives in the diagnostic process of heart failure: a scoping review.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Important differences in comorbidities and clinical characteristics exist between women and men with heart failure (HF). In particular, differences in the kinetics of biological circulating biomarkers-a critical component of cardiovascular care-are highly relevant. Most circulating HF biomarkers are assessed daily by clinicians without taking sex into account, despite the multiple gender-related differences observed in plasma concentrations. Even in health, compared to men, women tend to exhibit higher levels of natriuretic peptides and galectin-3 and lower levels of cardiac troponins and the cardiac stress marker, soluble ST2. Many biological factors can provide a reliable explanation for these differences, like body composition, fat distribution, or menopausal status. Notwithstanding, these sex-specific differences in biomarker levels do not reflect different pathobiological mechanisms in HF between women and men, and they do not necessarily imply a need to use different diagnostic cut-off levels in clinical practice. To date, the sex-specific prognostic value of HF biomarkers for risk stratification is an unresolved issue that future research must elucidate. This review outlines current evidence regarding gender-related differences in circulating biomarkers widely used in HF, the pathophysiological mechanisms underlying these differences, and their clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.